Interestingly, although the molecular information available in ALK+ NSCLC patients after ALK inhibitor treatment is limited, we also observed a robust trend in therapy-induced BIM upregulation in patient-derived cancer cells (Fig. 2), in agreement with other studies in EGFR-mutant NSCLC that propose BIM as a predictive biomarker of response [60]. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.